参考文献/References:
［1］Oberaigner W, Minicozzi P, Bielska-Lasota M, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade ［J］. Acta Oncol, 2012, 51(4): 441-453.
［2］Pinato DJ, Graham J, Gabra H, et al. Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical Platinum resistance ［J］. Cancer Treat Rev, 2013, 39(2): 153-160.
［3］肖波，余桂梅，孙秋实．新辅助化疗联合肿瘤细胞减灭术治疗Ⅲ～Ⅳ期卵巢癌的疗效分析［J］．实用癌症杂志，2017，32（4）：644-646．
［4］成莉，李琳，邢辉．首次肿瘤细胞减灭术与新辅助化疗后间隔性肿瘤细胞减灭术治疗Ⅲ和Ⅳ期卵巢癌患者后其对铂类药物耐药性及生存期的影响 ［J］．中国全科医学，2014，17（9）：1021-1025．
［5］LI Xu-hui, CHEN Xiang-jun, OU Wen-bin, et al. Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis ［J］. Int J Biochem Cell Biol, 2013, 45(5): 979-986.
［6］刘文彬，闫海山，牛红卫．紫杉醇联合顺铂治疗晚期卵巢癌的临床疗效观察 ［J］．肿瘤药学，2012，2（3）：220-222．
［7］Onda T, Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions［J］. Expert Rev Anticancer Ther, 2011, 11(7): 1053-1067.
［8］CHEN H-p, Charles NL, LI Y-y, et al. Epigallocatechingallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation ［J］. Exp Cell Res, 2013, 329(1): 17-26.
［9］Havrilesky LJ, Garfield CF, Barnett JC, et al. Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer［J］. Gynecol Oncol, 2012, 125(3): 631-634.
［10］CHAO Hongtu, WANG Li, HAO Jingli, et al. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro ［J］. Cancer Lett, 2013, 329(1): 17-26.
［11］边策，綦小蓉，姚奎，等．新辅助化疗对晚期卵巢癌治疗应用价值的评估及多因素分析 ［J］．实用妇产科杂志，2016，32（4）：266-271．
［12］杨静．中间性肿瘤细胞减灭术治疗中晚期卵巢癌后对铂类药物耐药性及患者生存期的影响 ［J］．现代中西医结合杂志，2015，24（15）：1665-1666, 1676．
［13］杨利娟，张波，杨永秀．新辅助化疗与初始肿瘤细胞减灭术治疗晚期卵巢癌疗效的系统评价 ［J］．中国实用妇科与产科杂志，2017，33（2）：171-176．
［14］张苗，刘艳，张洁．新辅助化疗在治疗晚期卵巢癌中的应用进展 ［J］．医学综述，2015，21（24）：4483-4485．
［15］张林风，孙文妹，李文娟．先期化疗联合肿瘤细胞减灭术后腹腔热灌注化疗治疗晚期卵巢癌的临床疗效分析 ［J］．实用癌症杂志，2016，31（9）：1495-1497．
相似文献/References:
[1]伍军平,陈宝霞,罗新,等.妊娠晚期胎死宫内合并卵巢癌破裂1例[J].中国计划生育和妇产科,2011,(03):0.
[2]张爱臣,佟玲玲.卵巢癌的诊治进展[J].中国计划生育和妇产科,2013,(01):0.
ZHANG Ai-chen,TONG Ling-ling.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(2):0.
[3]李慧,汤小晗,卢美松*.肝素结合表皮生长因子与卵巢癌顺铂化疗耐药性关系的研究[J].中国计划生育和妇产科,2016,(12):15.
LI Hui,TANG Xiao-han,LU Mei-song*.Study on relationship between HB-EGF and resistance of ovarian cancer to chemotherapy drug[J].Chinese Journal of Family Planning & Gynecotokology,2016,(2):15.
[4]卢丹华,洪莉*,杨将,等.Jagged1-STAT 3信号轴对卵巢癌细胞A 2780迁移能力的影响[J].中国计划生育和妇产科,2017,(8):72.
LU Dan-hua,HONG Li*,YANG Jiang,et al.Effect of Jagged1-STAT 3 signal axis on migration ability of ovarian cancer cell A 2780[J].Chinese Journal of Family Planning & Gynecotokology,2017,(2):72.
[5]石亚利,梁华茂*,姚颖.腹腔镜卵巢恶性肿瘤再分期手术临床分析（附38例报道）[J].中国计划生育和妇产科,2018,(3):37.
SHI Ya-li,LIANG Hua-mao*,YAO Ying.Clinical analysis of laparoscopic restaging surgery for ovarian
malignancies (report of 38 cases)[J].Chinese Journal of Family Planning & Gynecotokology,2018,(2):37.
[6]叶海琼,秦明丽,傅晓冬*.卵巢癌程序性细胞凋亡因子4的临床意义及对预后的评估[J].中国计划生育和妇产科,2018,(4):58.
YE Hai-qiong,QIN Ming-li,FU Xiao-dong*.Clinical significance and prognostic value of programmed cell death factor 4 in patients with ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(2):58.
[7]陈彩香*,文锦娣,杨海珍.子宫内膜异位症相关卵巢癌患者临床特点分析[J].中国计划生育和妇产科,2018,(4):62.
CHEN Cai-xiang*,WEN Jin-di,YANG Hai-zhen.Clinical characteristics of patients with endometriosis associated ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(2):62.
[8]范云龙,杨建华.微生物在卵巢癌发病机制与治疗中的作用[J].中国计划生育和妇产科,2018,(5):24.
[9]吴亚男,李红霞*,孟宪宁,等.子宫内膜异位症及卵巢癌患者血清脑源性神经营养因子水平的表达及意义[J].中国计划生育和妇产科,2018,(9):32.
WU Ya-nan,LI Hong-xia*,MENG Xian-ning,et al.Expression and significance of serum BDNF in patients with endometriosis and ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(2):32.
[10]曲慧.静脉用盐酸托烷司琼及联合沙利度胺治疗卵巢癌化疗所致恶心呕吐疗效及安全性研究[J].中国计划生育和妇产科,2018,(11):28.
QU Hui.Efficacy and safety of intravenous tropisetron hydrochloride combined with thalidomide in the treatment of nausea and vomiting induced by chemotherapy in ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(2):28.
[11]何丽,林永红,李笑晓,等.防己诺林碱联用紫杉醇对耐药卵巢癌SKOV3/ADM细胞作用机制的初步研究[J].中国计划生育和妇产科,2017,(6):59.
HE Li,LIN Yong-hong,LI Xiao-xiao,et al.Effect of fangchinoline combined with paclitaxel on drug resistant ovarian cancer SKOV3 / ADM cells: a preliminary study[J].Chinese Journal of Family Planning & Gynecotokology,2017,(2):59.